Spun out of Office of Technology Commercialization at Nationwide Childrenâs Hospital, LYST Therapeutics is structured around development of a platform technology for treatment of fibrotic diseases. Originally developed by researchers in the Center for Tissue Engineering at Nationwide Childrenâs Hospital, the firm's technology is a novel immunomodulatory therapeutic antibody having potential applications in the treatment of stenosis, myocardial infarction, and other conditions involving fibrosis. For their first therapeutic indication, LYST Therapeutics is applying their technology to the prevention of stenosis in tissue engineered vascular graft: to determine effect of LYST antibody on inhibiting the formation of tissue engineered vascular graft stenosi
